NCT03587311 2026-06-03Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting96 enrolled